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Abstract
Ovarian cancers are highly heterogeneous and while chemotherapy is the preferred treatment, many
patients are intrinsically resistant or quickly develop resistance. Furthermore, all tumors that recur
will become resistant. Recent evidence suggests that epigenetic deregulation may be a key factor in
the onset and maintenance of chemoresistance. To examine the ovarian epigenome, we first
analyzed a set of 43 primary ovarian tumors and 9 normal ovarian samples. Since therapy response
is a significant issue for ovarian cancer patients we analyzed the epigenetic differences that
segregate with platinum response. We then associated expression data to identify genes with
expression changes potentially altered by promoter methylation to generate a list of candidate
platinum resistance genes. Next, we developed a tissue culture carboplatin resistance screen to
determine which candidates functionally affect resistance. The screen utilized pools of shRNAs of
the candidate genes to identify genes that when repressed allowed survival from carboplatin
treatment, in order to validate that our epigenetics screen identified genes involved in resistance. Of
the genes identified in the screen we further characterized one gene, docking protein 2 (DOK2), an
adapter protein downstream of tyrosine kinase, to determine if we could elucidate what mechanism
was used to increase resistance. Our analysis determined that loss of DOK2 decreased the level of
apoptosis in response to carboplatin. In addition, we determined that in cells with reduced DOK2, the
level of anoikis was decreased, a mechanism of possible importance in ovarian cancer where there
is a large number of cells floating in ascites. Functional analysis of the DOK2 genes ability to affect
resistance validates this approach to finding genes involved in carboplatin resistance.

